Clinical Trial Update: A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating BMS-986158 alone and in combination with ruxolitinib or fedratinib in patients with myelofibrosis; the study status is active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• BMS-986158 (BMS-986158)
• Ruxolitinib (ruxolitinib)
• fedratinib (fedratinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING